article · Results in Chemistry
This study investigated four novel iminocoumarin derivatives for their antioxidant, anti-inflammatory, and antidiabetic properties using both in vitro experiments and in silico modelling. The compounds demonstrated significant antioxidant activity by inhibiting DPPH, and showed anti-inflammatory effects by reducing heat-induced erythrocyte hemolysis. Furthermore, they exhibited potent inhibitory effects against alpha-glucosidase and alpha-amylase, enzymes relevant to diabetes management. Artificial Neural Network (ANN) and Response Surface Methodology (RSM) models were applied, with ANN showing superior accuracy in predicting the compounds' activities. The findings suggest these molecules could be promising candidates for developing new therapeutic agents.
This research identifies new compounds with potential to combat conditions like oxidative stress, inflammation, and diabetes. By understanding their mechanisms and optimising their effects, scientists could develop more effective and targeted treatments, improving health outcomes for a range of prevalent diseases.
This early-stage research identifies novel iminocoumarin derivatives with antioxidant, anti-inflammatory, and antidiabetic properties. These findings could inform the development of new pharmaceutical ingredients or therapeutic compounds. Potential users include pharmaceutical companies or research organisations seeking to create improved treatments for conditions related to oxidative stress, inflammation, or diabetes.
AI-generated from the published abstract. Always read the original work before citing.
This study investigates four novel iminocoumarin derivatives (3–6), previously synthesized and characterized, for their antioxidant, anti-inflammatory, and antidiabetic properties at different concentrations (12.5, 25, 50, 100, 200, 400, 800, and 1600 g/mL). Artificial neural network (ANN) approaches and response surface methodology (RSM) were used in a two-variable process that comprised iminocoumarins and concentrations to determine the impact of these compounds on the parameters that were monitored. The results indicated that the 2.2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay investigated the antioxidant activity of the synthesized compounds. The compounds expressed a remarkable DPPH inhibitory effect with IC₅₀ values in the range of 45.04 and 108.61 μg/ml. The anti-inflammatory activity was evaluated using an in vitro heat-induced hemolysis method. At 400 μg/ml, the percentage of erythrocyte hemolysis inhibition of these compounds ranged from 18.23 ± 0.18 % to 64.52 ± 0.13 %. The antidiabetic activity was determined in vitro by the alpha-glucosidase and alpha-amylase inhibitory effects. The synthesized compounds were found to be potent inhibitors of alpha-glucosidase with IC₅₀ values ranging between 111.25 μg/ml and 337.2 μg/ml and alpha-amylase with IC₅₀ values ranging between 101.84 μg/ml and 339.81 μg/ml. Additionally, the synthesized compounds underwent a molecular docking study against alpha-amylase. Moreover, there is a good correlation between experimental data and the ANN and RSM models. The R 2 values for the inhibition of DPPH, alpha-glucosidase, alpha-amylase, and inflammation are 99.50 %, 98.96 %, 99.69 %, and 99.84 %, respectively; it is demonstrating the artificial neural network model's notable better accuracy and excellent agreement with the experimental findings. Thereby, the prepared molecules could serve as potential agents for the development of more powerful and effective antioxidants, anti-inflammatories, and antidiabetic compounds. • Four (2Z)-2-(arylimino)-2Hchromene-3-carboxamides were synthesized. • All compounds showed potent antioxidant and anti-inflammatory activities. • All compounds exhibited good to moderate inhibitory activity of alpha-glucosidase and alpha-amylase. • Molecular docking against alpha-amylase was conducted. • Response surface and artificial neural network modeling techniques were applied to four new iminocoumarin derivatives. • ANN outperformed RSM in the prediction of iminocoumarin derivatives.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.rechem.2025.102249
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
